About this trial
Coronary computed tomography angiography (CCTA) is a widely accepted initial diagnostic test for individuals suspected of having chronic coronary syndromes. However, there is limited evidence supporting its use in the acute setting. So far, no large-scale randomized trial has examined the performance of CCTA as an alternative to invasive coronary angiography (ICA) in individuals with non-ST-segment elevation myocardial infarction (NSTEACS).
If CCTA were to replace ICA as a routine procedure for individuals with NSTEACS, it could reduce the risk of complications related to ICA, improve patient comfort, expedite decision-making, and reduce healthcare expenses and interhospital transfers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Admitted with non-ST-segment elevation myocardial infarction or unstable angina pectoris and an indication for subacute ICA
Elevated troponin or ischemic electrocardiographic changes
Written informed consent
Disqualifiers
Instability requiring acute or emergent ICA
History of percutaneous coronary intervention or coronary artery bypass grafting
Estimated glomerular filtration rate < 30 mL/min/1.73m2
Probable type 2 acute myocardial infarction
Trial design
Parallel
Treatments tested in this trial
CCTA
Procedure/SurgeryParticipants will be examined with CCTA during admission.
Conventional ICA
Procedure/SurgeryPatients will be examined with conventional standard-of-care ICA.
Team-based interventional triage
Other interventionThe CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
Treatment groups
Trial outcomes
Primary outcomes
Number of participants with a combined endpoint of major adverse cardiac events
All-cause mortality, non-fatal myocardial infarction, hospitalization with refractory angina, or hospitalization with heart failure.
Secondary outcomes
Number of participants with a the individual composites of the primary outcome
All-cause mortality, non-fatal myocardial infarction, hospitalization with refractory angina, or hospitalization with heart failure.
Number of participants with cardiovascular death
Number of participants with unplanned coronary revascularization
Health-related Quality of life
Measured by EQ-5D-5L
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Rigshospitalet, Denmark
Lead sponsor
University of Copenhagen
Collaborator